ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients
Our lead product, leronlimab (PRO 140), belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection. Leronlimab (PRO 140) has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments.
Our CMO Dr. Richard Pestell, MD, PhD, MB, BS, FACP, FRACP, FAAAS, MBA, is a world renowned oncologist and researcher. Dr. Pestell has played an instrumental role in identifying the role of CCR5 in cancer indications, and has worked to develop CCR5 technology